Large Neuronetics (STIM) holder discloses 15.17% stake and sole control
Rhea-AI Filing Summary
Neuronetics, Inc. investor Jorey Chernett reports a 15.17% ownership stake in the company’s common stock. As of the close of business on May 26, 2026, he beneficially owned 10,553,988 shares, based on 69,587,840 shares outstanding as of May 1, 2026.
The filing states that these shares were purchased with personal funds for an aggregate price of approximately $20,619,936. Chernett holds sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. An exhibit lists individual share transactions since the prior amendment.
Positive
- None.
Negative
- None.
Insights
Investor reports a sizable, 15.17% sole-controlled stake in Neuronetics.
Jorey Chernett discloses beneficial ownership of 10,553,988 shares of Neuronetics common stock, representing approximately 15.17% of outstanding shares as of May 1, 2026. The stake was acquired using personal funds totaling about $20,619,936, indicating a meaningful financial commitment.
The filing notes sole voting and sole dispositive power over all reported shares, which concentrates decision-making for this block with one holder. No other party is identified as sharing rights to dividends or sale proceeds. The attached exhibit of recent trades may help contextualize how the position evolved since the last amendment.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
Schedule 13D regulatory
Percent of class financial
AI-generated analysis. How Rhea-AI works. Not financial advice.